MarketBeat
21 Jun 2026, 14:31 UTC · 13w ago
Verdict
Headline takes no side. We score KRYS +0.80 across four claims — strongly bullish.
+0.80strongly bullish
More positive than 86% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Vera Therapeutics (VERA) plans to submit a Biologics License Application (BLA) for atacicept by the end of the year, pending Q3 eGFR analysis results.
So whatFDA approval would grant access to a $20-billion market, while a failure or delay would be severely detrimental to a clinical-stage company.
More positive than 99% of claims this week
Krystal Biotech (KRYS) expects top-line results for its KB803 corneal abrasion treatment by the end of this year.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Search tags
More positive than 93% of claims this week
ADMA Biologics (ADMA) is experiencing margin expansion driven by new manufacturing efficiencies and 28% YOY growth in ASCENIV revenue.
More positive than 77% of claims this week
Krystal Biotech's Vyjuvek reported first-quarter revenue of $116 million, a 32% year-over-year increase.
More positive than 64% of claims this week
Which stocks this story touches
More positive than 86% of ticker scores this week
Strong revenue growth from Vyjuvek and positive momentum from upcoming data readouts for new candidates.
More positive than 74% of ticker scores this week
Bullish analyst ratings and potential for significant commercial growth following a pending FDA decision on atacicept.
More positive than 68% of ticker scores this week
Strong revenue growth, margin expansion, and attractive valuation despite a year-to-date price decline.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Proactive Investors
15h ago
−1.8%
Price is moving against the score
$341.75 vs $348.06 close before publication (Jun 18) · not market-adjusted
KRYS chart →
